Extracted from this filing and checked against the source text.
Distress & Bankruptcy
SEC 8-K Item 1.03
confidence 0.9
Clearside Biomedical, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2025-11-23).
- Proceeding
- chapter 11
- Court
- United States Bankruptcy Court for the District of Delaware
- Petition
- 2025-11-23
Exact text from the filing
On November 23, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a voluntary petition (Case No. 25-12109) for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “ Court ” and such case, the “ Case ”).
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Clearside Biomedical, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
- Exchange
- nasdaq
- Notice
- delisting notice
- Rules
- 5101, 5110(b), IM-5101-1
Exact text from the filing
November 24, 2025, the Company received written notice (the “ Delisting Notice ”) from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Case and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq has determined that the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), will be delisted from Nasdaq. In addition, as previously disclosed, on August 28, 2025, the Company received written notice (the “ MVLS Notice ”) from Nasdaq notifying the Company that it is not in compliance with t
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Clearside Biomedical, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).
- Exchange
- nasdaq
- Notice
- noncompliance notice
- Deficiency
- market value
- Rules
- 5450(b)(2)(A)
Exact text from the filing
August 28, 2025, the Company received written notice (the “ MVLS Notice ”) from Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securities of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing that certain MVLS Notice. Trading of the Common Stock will be suspended at the opening of
View on SEC.gov